The Rest of Europe region, including Nordic countries, Eastern Europe, Belgium, Switzerland, and Austria, is anticipated to hold 16.6% in 2025, declining slightly to 16.3% by 2035, attributed to mixed growth patterns with strong expansion in some healthcare markets balanced by moderate growth in smaller countries implementing diabetes care development programs
Witness Statements: Statements from family members, nurses, staff, or others who observed the patients condition or treatment
GLP-1 therapies now represent one of the fastest-growing segments of employer pharmacy spend, driven by their premium pricing and eligibility that extends well beyond traditional obesity populations
Additionally, these electrodes are linked to a pulse generator implanted in the thoracic cavity